COO Healthcare

The Cooper Companies, Inc.

$60.83-0.77%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 11.6B USD
Enterprise value: 13.4B USD
Full-time employees: 15,000

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: less short-term liquidity (current ratio 1.22 vs a peer median of 2.59)less liquidity (current ratio 1.22 vs peers 2.59)
About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #472 of 1,157 healthcare companies (top 41%)

See how it ranks against its peers

Worth knowing

Buybacks largely absorbed by stock pay. Stock-based pay expense $208M vs $290M spent repurchasing shares over the 3 fiscal years to FY Oct 2025. Shares outstanding changed −3.6% from October 2022 to September 2026.
Over three fiscal years Cooper Companies recorded $208M of stock-based pay expense and spent $290M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). The share count barely moved (−3.6%), so much of the repurchasing offset new employee shares rather than shrinking the count.Over three fiscal years Cooper Companies recorded $208M of stock-based pay expense and spent $290M repurchasing shares. The share count barely moved (−3.6%), so much of the repurchasing offset new employee shares rather than shrinking the count.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in FY Oct 2020 to $4.1B in FY Oct 2025.
Cooper Companies's fiscal-year revenue rose in each of the five years to FY Oct 2025, from $2.4B to $4.1B.
Profit is backed by cash. Free cash flow is 119% of reported profit.
Cooper Companies's free cash flow is 119% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

56/ 100▲ 1 since Oct 27 close

Oct 5 56 → Nov 4 56

Valuation

Is the price right?

70/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 2.5%

Valuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield4.9%

SEC filings · 12 months to Jul 2026Reported value30% base weight · Z-score 2.33Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.7%

SEC filings · 12 months to Jul 2026Reported value50% base weight · Z-score 0.66Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield5.9%

SEC filings · 12 months to Jul 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield72.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

57/100

Moderate▲ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Score 56 → 57

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Helped by:

▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth46.2%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 1.22Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth6.4%

SEC filings · 3 years to Jul 2026Reported value33% base weight · Z-score 0.07Sector median: 0.0584 · MAD: 0.0840

Revenue growth4.7%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -0.14Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

60/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROA
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin12.8%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 0.48Sector median: 0.0706 · MAD: 0.1217

Return on assets4.5%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 0.53Sector median: 0.0166 · MAD: 0.0537

Return on invested capital4.0%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -0.07Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin65.9%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity6.8%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.82

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.59Sector median: 0.6250 · MAD: 0.3380

Current ratio1.22×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.98Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.31×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.41Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Cooper Companies

Is Cooper Companies getting weaker?: Its latest SEC filing (Sep 9, 2026) got stronger: share count down 2.5%. Its overall score is 56/100, up 1 since Oct 28, 2026.
How is Cooper Companies valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 70/100 against 1,393 healthcare peers. Earnings yield 4.9% vs a peer median of 1.5% (stronger than 77% of peers).Earnings yield 4.9% vs peers 1.5% (stronger than 77% of peers).
Is Cooper Companies growing?: At about the same pace as its peers. Growth scores 57/100 against 1,393 healthcare peers. Earnings per share growth 46.2% vs a peer median of 9.8% (stronger than 79% of peers).Earnings per share growth 46.2% vs peers 9.8% (stronger than 79% of peers).
How profitable is Cooper Companies?: More profitable than most of its peers. Profitability scores 60/100 against 1,393 healthcare peers. Return on assets 4.5% vs a peer median of 1.7% (stronger than 69% of peers).Return on assets 4.5% vs peers 1.7% (stronger than 69% of peers).
How risky is Cooper Companies?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.22× vs a peer median of 2.59× (weaker than 83% of peers).Current ratio 1.22× vs peers 2.59× (weaker than 83% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jul 31, 2026 · filed Sep 9, 2026 · compared with the quarter ended Apr 30, 2026

Got stronger

Share count down 2.5%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4.2B USD	4.2B USD	+0.1%
Net income (12 months)	235.8M USD	570.3M USD	+141.9%
Operating margin	11.8%	12.8%	+1.1 pts
Free cash flow (12 months)	569.5M USD	678.0M USD	+19.1%
Debt	2.5B USD	2.5B USD	+3.4%
Cash	138.8M USD	154.7M USD	+11.5%
Shares outstanding	195.0M	190.2M	−2.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Oct 2021	FY Oct 2022	FY Oct 2023	FY Oct 2024	FY Oct 2025	Change
Gross margin	66.9%	64.7%	65.6%	66.6%	65.5%	▼ 1.1 pts
Operating margin	17.3%	15.3%	14.8%	18.1%	16.7%	▼ 1.4 pts
Net margin	100.8%	11.7%	8.2%	10.1%	9.2%	▼ 0.9 pts
Return on assets (ROA)	30.7%	3.4%	2.5%	3.2%	3.0%	▼ 0.2 pts
Return on equity (ROE)	42.4%	5.4%	3.9%	4.9%	4.6%	▼ 0.3 pts
Free cash flow margin	17.9%	13.6%	6.0%	7.4%	10.6%	▲ 3.2 pts
Current ratio	2.00×	1.20×	1.76×	1.91×	1.89×	▼ 0.8%
Quick ratio	1.20×	0.71×	1.00×	1.12×	1.13×	▲ 0.8%
Debt to equity	0.21×	0.39×	0.34×	0.32×	0.30×	▼ 4.9%
Interest coverage	21.90×	8.86×	5.06×	6.17×	6.83×	▲ 11%

COO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: less short-term liquidity (current ratio 1.22 vs a peer median of 2.59)less liquidity (current ratio 1.22 vs peers 2.59)

About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #472 of 1,157 healthcare companies (top 41%)

See how it ranks against its peers

Worth knowing

Buybacks largely absorbed by stock pay. Stock-based pay expense $208M vs $290M spent repurchasing shares over the 3 fiscal years to FY Oct 2025. Shares outstanding changed −3.6% from October 2022 to September 2026.

Over three fiscal years Cooper Companies recorded $208M of stock-based pay expense and spent $290M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). The share count barely moved (−3.6%), so much of the repurchasing offset new employee shares rather than shrinking the count.Over three fiscal years Cooper Companies recorded $208M of stock-based pay expense and spent $290M repurchasing shares. The share count barely moved (−3.6%), so much of the repurchasing offset new employee shares rather than shrinking the count.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in FY Oct 2020 to $4.1B in FY Oct 2025.

Cooper Companies's fiscal-year revenue rose in each of the five years to FY Oct 2025, from $2.4B to $4.1B.

Profit is backed by cash. Free cash flow is 119% of reported profit.

Cooper Companies's free cash flow is 119% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Cooper Companies

Is Cooper Companies getting weaker?

Its latest SEC filing (Sep 9, 2026) got stronger: share count down 2.5%. Its overall score is 56/100, up 1 since Oct 28, 2026.

How is Cooper Companies valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 70/100 against 1,393 healthcare peers. Earnings yield 4.9% vs a peer median of 1.5% (stronger than 77% of peers).Earnings yield 4.9% vs peers 1.5% (stronger than 77% of peers).

Is Cooper Companies growing?

At about the same pace as its peers. Growth scores 57/100 against 1,393 healthcare peers. Earnings per share growth 46.2% vs a peer median of 9.8% (stronger than 79% of peers).Earnings per share growth 46.2% vs peers 9.8% (stronger than 79% of peers).

How profitable is Cooper Companies?

More profitable than most of its peers. Profitability scores 60/100 against 1,393 healthcare peers. Return on assets 4.5% vs a peer median of 1.7% (stronger than 69% of peers).Return on assets 4.5% vs peers 1.7% (stronger than 69% of peers).

How risky is Cooper Companies?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.22× vs a peer median of 2.59× (weaker than 83% of peers).Current ratio 1.22× vs peers 2.59× (weaker than 83% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4.2B USD

4.2B USD

+0.1%

Net income (12 months)

235.8M USD

570.3M USD

+141.9%

Operating margin

11.8%

12.8%

+1.1 pts

Free cash flow (12 months)

569.5M USD

678.0M USD

+19.1%

Debt

2.5B USD

2.5B USD

+3.4%

Cash

138.8M USD

154.7M USD

+11.5%

Shares outstanding

195.0M

190.2M

−2.5%

Key ratios

FY Oct 2021

FY Oct 2022

FY Oct 2023

FY Oct 2024

FY Oct 2025

Change

Gross margin

66.9%

64.7%

65.6%

66.6%

65.5%

▼ 1.1 pts

Operating margin

17.3%

15.3%

14.8%

18.1%

16.7%

▼ 1.4 pts

Net margin

100.8%

11.7%

8.2%

10.1%

9.2%

▼ 0.9 pts

Return on assets (ROA)

30.7%

3.4%

2.5%

3.2%

3.0%

▼ 0.2 pts

Return on equity (ROE)

42.4%

5.4%

3.9%

4.9%

4.6%

▼ 0.3 pts

Free cash flow margin

17.9%

13.6%

6.0%

7.4%

10.6%

▲ 3.2 pts

Current ratio

2.00×

1.20×

1.76×

1.91×

1.89×

▼ 0.8%

Quick ratio

1.20×

0.71×

1.00×

1.12×

1.13×

▲ 0.8%

Debt to equity

0.21×

0.39×

0.34×

0.32×

0.30×

▼ 4.9%

Interest coverage

21.90×

8.86×

5.06×

6.17×

6.83×

▲ 11%